anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
One primary metabolic manifestation of inflammation is the diversion of cis-aconitate within the tricarboxylic acid (TCA) cycle to synthesize the immunometabolite itaconate. Itaconate is well established to possess immunomodulatory and metabolic effects within myeloid cells and lymphocytes, however, its effects in other organ systems during sepsis remain less clear. Utilizing Acod1 knockout mice that are deficient in synthesizing itaconate, we aimed to understand the metabolic role of itaconate in the liver and systemically during sepsis. We find itaconate aids in lipid metabolism during sepsis. Specifically, Acod1 KO mice develop a heightened level of hepatic steatosis when induced with polymicrobial sepsis. Proteomics analysis reveals enhanced expression of enzymes involved in fatty acid oxidation in following 4-octyl itaconate (4-OI) treatment in vitro. Downstream analysis reveals itaconate stabilizes the expression of the mitochondrial fatty acid uptake enzyme CPT1a, mediated by its hypoubiquitination. Chemoproteomic analysis revealed itaconate interacts with proteins involved in protein ubiquitination as a potential mechanism underlying its stabilizing effect on CPT1a. From a systemic perspective, we find itaconate deficiency triggers a hypothermic response following endotoxin stimulation, potentially mediated by brown adipose tissue (BAT) dysfunction. Finally, by use of metabolic cage studies, we demonstrate Acod1 KO mice rely more heavily on carbohydrates versus fatty acid sources for systemic fuel utilization in response to endotoxin treatment. Our data reveal a novel metabolic role of itaconate in modulating fatty acid oxidation during polymicrobial sepsis.
PROBLEM TO BE SOLVED: To obtain the new subject compound having antitumor action and useful as an antitumor agent. SOLUTION: This antitumor material BE-51068 is expressed by the formula and has the following physical properties; description: a yellow oily material; molecular formula: C26 H30 O4 ; mass analysis: [high resolution FAB-MS] measured value 405.2079, calculated value 405.2065 as (M-H)<+> ; solubility: easily soluble in organic solvents such as dimethylsulfoxide, etc., sparingly soluble in water; discrimination among an acidic, a neutral and a basic material: a neutral material; color reaction: positive to sulfuric acid reaction and phosphomolybdic acid reaction. The compound is obtained from a culture product obtained by culturing a microorganism or its variant [e.g. a new microorganism, Streptomyces sp. A 5106 (FERM P-15623)] having ability to produce the compound of the formula.  The culture is preferably carried out at 18-29 deg.C and pH 4-8 for 72-168 hours by a shaking culture or an agitation culture with deep aeration. A dose of the compound of the formula is preferably 10-500mg for an adult per day in case of an oral administration.
The single group in this study will consist of individuals enrolled in the parent study (ClinicalTrials.gov identifier NCT04430517). We aim to enroll approximately 40 individuals aged 18 -89 (inclusive) with either MCI or mild AD who will have the Emerald device deployed in their home for up to 12 weeks, spanning the time of approval of parent study screening and formal study enrollment.
Participants will receive the descriptive medication by neurologist in addition to electromagnetic therapy. Electromagnetic therapy will be applied for 20 min/session for three days each week for two months.
<P>PROBLEM TO BE SOLVED: To provide a medical drug containing a new benzoazepine compound suitable for use as an injectable solution in which solubility of tolvaptan in water is enhanced.  <P>SOLUTION: The present invention provides a medical drug containing a benzoazepine compound represented by general formula (1) or a salt thereof. In the formula, R represents a hydrogen atom, a hydroxy group or the like optionally having a protective group. R<SP>1</SP>represents a hydrogen atom or a hydroxy protective group. X represents an oxygen atom or a sulfur atom.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Patients hepatoblastoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
The need for intervention due to postoperative bleeding represents a significant complication in Thulium Laser Enucleation of the Prostate (ThuLEP). This study aimed to retrospectively analyse this complication in the treatment of benign prostatic enlargement. This study focuses on investigating potential causative factors for postoperative bleeding requiring intervention as well as the use of intraoperative electrocoagulation. A total of 503 ThuLEP procedures performed between 08/2021 and 07/2022 were examined. Postoperatively, 4.2% (n=21) of patients experienced bleeding requiring intervention. Study data revealed a significant association between these instances of bleeding and a high prostate volume (p=0.004), high enucleation weight (p=0.004), and intraoperative electrocoagulation (p=0.048). In total, intraoperative electrocoagulation was applied in 41.2% (n=207) of cases. In these cases, statistically significant factors leading to the application of electrocoagulation included intraoperative capsule perforation (p=0.005) and high enucleation weight (p=0.002).
It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercice is conducted at the end of each session. A CD with the audiotaped hypnosis exercice is given to each patient so that they can practice also every day.
<P>PROBLEM TO BE SOLVED: To obtain a cosmetic composition comprising a pearlescent pigment having both excellent touch characteristics and excellent optical characteristics.  <P>SOLUTION: This cosmetic composition is characterized as comprising the pearlescent pigment having the surface treated with >5 to <15 wt.% of an N-acylated lysine. N-Lauroyllysine is preferred as the N-acylated lysine. The pearlescent pigment having the surface treated with the N-lauroyllysine is preferably formulated in an amount of 0.5-25 wt.% in the composition. The smoothness of the platy pearlescent pigment is improved and even optical characteristics thereof are improved in the cosmetic composition by the surface treatment with the N-lauroyllysine. Furthermore, a natural finish can be obtained.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
A cosmetic wipe that contains a first nonwoven layer having first and second opposing surfaces is provided. The first nonwoven layer contains fibers formed from a polymer composition and is generally opaque in nature. A second nonwoven layer is laminated to the first surface of the first nonwoven layer. The second nonwoven layer contains a colorant that imparts a certain color to the second layer. Prior to use, the colored second layer is not generally visible when viewed from the second surface of the first layer due to the opaque nature of the first layer. However, sebum or other bodily oils absorbed by the first layer during use can prevent light from adequately reflecting from the layer. Thus, at least a portion of the first layer becomes translucent or transparent so that the color of the second layer becomes visible to a user. This provides a variety of benefits, including the ability for a user to evaluate if or how much sebum was removed from the skin so that makeup, etc. can be applied with confidence.
In individuals with hearing loss, protection of residual hearing is essential following cochlear implantation to facilitate acoustic and electric hearing. Hearing preservation requires slow insertion, atraumatic electrode and delivery of the optimal quantity of a pharmacological agent. Several studies have reported variable hearing outcomes with osmotic pump-mediated steroid delivery. New drugs, such as sialyllactose (SL) which have anti-inflammatory effect in many body parts, can prevent tissue overgrowth. In the present study, the positive effects of the pharmacological agent SL against insults were evaluated in vitro using HEI-OC1 cells. An animal model to simulate the damage due to electrode insertion during cochlear implantation was used. SL was delivered using osmotic pumps to prevent loss of the residual hearing in this animal model. Hearing deterioration, tissue fibrosis and ossification were confirmed in this animal model. Increased gene expressions of inflammatory cytokines were identified in the cochleae following dummy electrode insertion. Following the administration of SL, insertion led to a decrease in hearing threshold shifts, tissue reactions, and inflammatory markers. These results emphasize the possible role of SL in hearing preservation and improve our understanding of the mechanism underlying hearing loss after cochlear implantation.
After surgery, in the post-operative recovery room, patients randomized to both the intervention and control groups will have 10cc 0.5% ropivacaine bolused via their nerve catheters. After 30 minutes, the following will be measured/assessed: spirometry data, pain scores (using the Numeric Rating Scale), and, if time is sufficient, bilateral diaphragmatic excursion via ultrasonography and brachial plexus motor and sensory exams. This control group will have no normal saline injected into their nerve catheter (no intervention). Then, both the control and treatment groups will have the following measured/assessed after 5, 15 and 30 minutes: spirometry data, pain scores (using the Numeric Rating Scale), and, if time is sufficient, bilateral diaphragmatic excursion via ultrasonography and brachial plexus motor and sensory exams. Investigators will be blinded to whether the patient is in the intervention or treatment group.
Furosemide is a diuretic which is an anthranilic acid derivative. Chemically, it is 4-chloro-N-furfuryl-5-sulfamoylanthranilic acid. Furosemide is a white to slightly yellow, odorless, crystalline powder. Practically insoluble in water; freely soluble in acetone, in dimethylformamide, and in solutions of alkali hydroxides; soluble in methanol; sparingly soluble in alcohol; slightly soluble in ether; very slightly soluble in chloroform.

The structural formula is as follows:

Furosemide Injection, USP is a sterile, nonpyrogenic solution of furosemide in Water for Injection prepared with the aid of sodium hydroxide for intramuscular (IM) or intravenous (IV) use. 

Each mL contains: Furosemide 10 mg; Water for Injection q.s.; sodium chloride to adjust isotonicity; sodium hydroxide and if necessary hydrochloric acid to adjust pH between 8.0 and 9.3.
PURPOSE:To obtain a novel diuretic having excellent diuretic action, electrolyte- secretion promoting action and uric acid secretion promoting action, by using a phenoxyacetic acid derivative or its salt as an active component. CONSTITUTION:The objective agent can be produced by using a compound of formula I (R<1> is H or lower alkyl; R<2> is H or lower alkenyl; R<3> is H, lower alkyl, lower alkoxy-substituted-lower alkyl, etc., X is halogen; Z is O or methyl ene) or its salt as an active component, compounding the component with a conventional drug carrier and converting to a drug preparation by conventional method. It can be administered orally or parenterally at a dose of 0.3-200mg/kg daily. The compound of formula I can be produced by reacting a phenol deriva tive of formula II with an acetic acid compound of formula Y-CH2COOR<1> (Y is halogen) in a solvent in the presence of an acid acceptor (e.g. alkali metal hydroxide) at room temperature or under heating. The compound of formula I is e.g. {2,3-dichloro-4-[1-(1-ethoxymethyl-5-pyrazolyl)vinyl] phenoxy} acetic acid.
Participants treated by cabozantinib who received systemic therapy and/or had prolonged treatment-free interval (≥ 12 weeks) between two cabozantinib treatment periods. Participants with at least one cabozantinib rechallenge could be included in this subgroup.
The purpose of this study is to develop the core competence and training model for case management of dementia. In the previous year (phase I), the needs and competence assessment stage, the investigators are conducting a survey of the connotation and needs of dementia case management, and explore the role functions and competencies of dementia case managers as the basis for developing the training program.

This study is the second phase of the project. The first year is the establishment of the training program and the pilot-test stage. The data collected in the previous period will be integrated to plan a preliminary training program structure, and then the content and training methods of the training program for dementia case managers will be established using the Delphi method. Then, use this training program to carry out the pilot test of the dementia case managers training program. The second year is the project implementation and effectiveness evaluation stage, the intervention effectiveness evaluation of the training course for dementia case managers will be conducted. The results of this study will serve as a reference for the training program of dementia case managers in future.
Participants will receive active tDCS with an intensity 2 mA for 20 minutes and a telerehabilitation exercise program for 50 minutes. The program will be implemented over 12 sessions, occurring three times a week for four weeks).
Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.
Participants will receive a peritoneal dialysis catheter implant. DSR is to be started 14 days after catheter implantation (= D1) for a period of 4 weeks (D28) on top of optimized usual care for HF, while loop diuretic treatment is suspended. Participants then enter enter a 3 month safety follow-up period (D29-D120) until the end of study (D120).
The knowledge of the blood microvasculature and its functional role in health and disease has grown significantly attributable to decades of research and numerous advances in cell biology and tissue engineering; however, the lymphatics (the secondary vascular system) has not garnered similar attention, in part due to a lack of relevant in vitro models that mimic its pathophysiological functions. Here, a microfluidic-based approach is adopted to achieve precise control over the biological transport of growth factors and interstitial flow that drive the in vivo growth of lymphatic capillaries (lymphangiogenesis). The engineered on-chip lymphatics with in vivo-like morphology exhibit tissue-scale functionality with drainage rates of interstitial proteins and molecules comparable to in vivo standards. Computational and scaling analyses of the underlying transport phenomena elucidate the critical role of the three-dimensional geometry and lymphatic endothelium in recapitulating physiological drainage. Finally, the engineered on-chip lymphatics enabled studies of lymphatic-immune interactions that revealed inflammation-driven responses by the lymphatics to recruit immune cells via chemotactic signals similar to in vivo, pathological events. This on-chip lymphatics platform permits the interrogation of various lymphatic biological functions, as well as screening of lymphatic-based therapies such as interstitial absorption of protein therapeutics and lymphatic immunomodulation for cancer therapy.
SCUBA diving poses risks due to pressure changes during descent (compression) and ascent (decompression). Decompression sickness (DCS) occurs due to gas bubble formation as the pressure decreases, causing joint pain, numbness, dizziness, or even paralysis and death. Immediate treatment involves 100% oxygen to help eliminate inert gases and hyperbaric oxygen therapy (HBOT), which is essential to reduce gas emboli formation and inflammation, thus improving symptoms. We evaluated oxy-inflammation biomarkers in the saliva and urine of nine subjects pre- and post-technical dive on the Haven wreck (GE, Italy). A case of DCS occurred during the dive. The injured diver was treated immediately with O2 and transported to the hyperbaric center of "ASST Ospedale Ca Granda" in Milan. He was treated following the U.S. Navy Treatment Table 5 at 2.8 ATA and the day after with Table 15 at 2.4 ATA. Venous blood and urine samples were collected before and after each HBO treatment. Our study shows that dive increased oxy-inflammation biomarkers (ROS +126%; lipid peroxidation +23%; interleukins-6 +81%, -1β +19%, and TNFα +84%) and nitric oxide metabolites levels (+36%). HBOT after a DCS episode reduced oxidative stress, lowering the very high marker of lipid peroxidation (8-iso-PGF2α), and inhibited inflammatory interleukins. Overall, HBOT improved physiological responses in the diver affected by DCS.
A 30-minute, picture enhanced power point presentation will be offered to all Operating Engineers during their annual safety trainings. The content of the power point presentation will include information on incidence and prevalence of skin cancer especially among outdoor workers, types of skin cancers and skin cancer risk, sunburn, Sun Protection Factor (SPF), sun protection behaviors including sunscreen use, correct application of sunscreen, types of products, and the new Food and Drug Administration (FDA) labeling of sunscreen products. In addition, other sun protection behaviors such as wearing hats, sunglasses, using shade, etc., will be discussed.
Respiratory distress syndrome (RDS) is a syndrome in premature infants caused by developmental insufficiency of surfactant production and structural immaturity in the lungs. Exogenous surfactant therapy has become well established in newborn infants with RDS. Surfactant replacement therapy, either as a rescue treatment or a prophylactic, reduces mortality and several aspects of morbidity in babies with RDS. It is known that infants who are at a significant risk of RDS should receive prophylactic surfactant therapy, but the optimal timing and strategy for prophylactic surfactant therapy remains controversial. When administered immediately after delivery, surfactant mixes with the fetal lung fluid and reaches the alveoli before the onset of lung injury potentially created by the first applied positive pressure ventilation. As another approach, surfactant prophylaxis may be administered after resuscitation and stabilization.
One of the most devastating complications following endovascular aneurysm repair (EVAR) is infection of the used endoprosthesis. Because of the high mortality of secondary surgery following infection, patients with a possible endoprosthesis infection are treated using broadspectrum antibiotics during months, years or even life-long. Unfortunately, the diagnosis of an endoprosthesis infection is difficult and based upon clinical suspicion and non-specific symptoms (e.g. fever and weigth loss) only. Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) is often used as a diagnostic tool to identify infection following EVAR. Like infection, sterile physiologic inflammation following EVAR is also associated with increased metabolism and FDG uptake. This could result in (false-)positive PET imaging resulting in diagnostic errors and antibiotic overuse.

The Nellix endoprosthesis is a relatively new device used for EVAR. In present literature there is no data on the degree of physiologic inflammation following implantation of a Nellix device and the value of postoperative FDG-PET imaging to detect infection is not known. This makes the diagnosis of infection following Nellix implantation extremely difficult. This pilot is designed to determine physiologic FDG uptake following uncomplicated EVAR using the Nellix endoprosthesis.
The attribution of value to prospects is a fundamental element of decision-making, as most day-to-day decisions involve comparing items. Studies on aging document behaviors reflecting difficulties in making comparisons between options, in particular when those options are complex. Given the growing complexity of economic products (insurance, savings, mortgages or even telephone plans), older adults may have difficulty making decisions that accurately reflect their underlying preferences. It is plausible that this difficulty is linked to age-related brain function decline within sectors of the lateral prefrontal cortex implicated in working memory and cognitive control. This study assesses age-related changes in how the brain computes value and makes value comparisons using a well-established economic paradigm, the "generalized axiom of revealed preference" (GARP) Task, that tests the internal consistency of a subject's preferences by offering repeated choices between bundles of goods. A preliminary study suggests that aging is associated with greater GARP-Task inconsistency. Although the neural correlates of GARP inconsistency have not been directly established, indirect evidence suggests that the medial orbitofrontal cortex is important in all value-based decision-making, and that areas in the lateral prefrontal and parietal cortices (fronto-parietal network) are important for maintaining consistency in complex decisions (e.g., multi-attribute decisions). Aging is associated with structural and functional deficits within the fronto-parietal network. Therefore, the investigators believe that studying the neural correlates of the GARP-Task is a promising approach to investigate decision-making deficits in aging. The investigators will recruit 45 young adults, and 45 old adults. Participants will complete the GARP-Task and an functional Magnetic resonance imaging (fMRI) variant designed to isolate neural correlates of valuation of single items, of multiple instances of the same item ("scaling") and of sets of distinct items ("bundles"). Brain activity will be related to diagnosis and to variance in GARP-Task inconsistency. Given the prominence of age-related decline in working memory, the investigators hypothesize that age will be associated with higher GARP-Task inconsistency and to deficits in conditions that require manipulation of value signals (scaling and bundles). The investigators anticipate that these deficits will be associated with low recruitment within the fronto-parietal network and with reduced functional connectivity between this network and the medial Orbitofrontal Cortex (OFC).
The present invention relates to treating or preventing stenosis at an anastomosis site. In one embodiment, the present invention is a stent is curved along the longitudinal axis for placement in and adjacent to the graft orifice. In a further embodiment, the stent is drug coated to allow delivery of antivasculoproliferative drugs directly to the vicinity of the graft orifice. In a further embodiment, the stent is expandable by use of an external wire. In another embodiment, the present invention is a kit comprising the specially configured stent together with a sleeve comprising a biocompatible matrix material and a pharmaceutical agent, wherein the sleeve is applied to the external surface of the vessel or graft, resulting in extravascular delivery of a pharmaceutical agent. Methods for treating or preventing stenosis at an anastomosis site by applying the extravascular sleeve and the intravascular stent are also provided.